Octafil Low (Human Coagulation Factor Viii)

Human Coagulation Factor VIII, the active ingredient in Octafil Low, is a coagulation factor VIII concentrate presented as an intravenous solution for intravenous use. It replaces deficient factor VIII in patients with hemophilia A, helping to control and prevent bleeding episodes.

GNH USA supplies Octafil Low as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Octafil Low is a factor VIII concentrate used in the management of bleeding disorders related to factor VIII deficiency. - Hemophilia A (congenital): provides factor VIII replacement to prevent or control spontaneous and trauma‑induced bleeds. - Acquired hemophilia A: supplies exogenous factor VIII to counteract auto‑antibody mediated deficiency. - Peri‑operative management of hemophilia A: ensures adequate factor VIII levels before, during and after surgery to reduce intra‑operative bleeding. - Prophylaxis in severe hemophilia A: maintains trough factor VIII activity to minimize the frequency of bleeding episodes.

Octafil Low may be associated with infusion‑related and immunologic reactions.

Common Side Effects: - Fever: mild to moderate temperature elevation during or after infusion. - Headache: transient discomfort following administration. - Nausea: occasional gastrointestinal upset. - Injection site erythema: mild redness at the infusion site. - Hypertension: temporary rise in blood pressure. - Mild arthralgia: joint discomfort without swelling.

Serious or Rare Side Effects: - Development of inhibitors: neutralizing antibodies that reduce efficacy. - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Thromboembolic events: rare clot formation in veins or arteries. - Severe hypertension: significant blood pressure elevation. - Hemolysis: breakdown of red blood cells. - Renal impairment: decreased kidney function observed in rare cases.

Octafil Low requires careful clinical monitoring and adherence to handling guidelines. - Inhibitor testing: assess for anti‑factor VIII antibodies before initiating therapy. - Renal function: evaluate kidney status in patients with pre‑existing impairment. - Cardiovascular risk: monitor blood pressure and cardiac status during infusion. - Pregnancy and lactation: use only if the potential benefit outweighs potential risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octafil Low may interact with other agents affecting hemostasis.

Major Interactions (Avoid): - Activated pro‑thrombin complex concentrates: combined use can markedly increase thrombotic risk. - High‑dose aspirin or other antiplatelet drugs: may exacerbate bleeding despite factor replacement.

Moderate Interactions (Monitor Closely): - Immunosuppressants (e.g., rituximab): may influence inhibitor development. - Antibiotics such as vancomycin: can cause infusion‑related reactions. - Concomitant use of other clotting factor products: requires dose adjustment and close monitoring.